Text Size

Strategies to Improve Asthma

This study is currently recruiting participants.
Verified May 2012 by Ottawa Hospital Research Institute
Sponsor:
Information provided by (Responsible Party):
Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier:
NCT01525381
First received: January 31, 2012
Last updated: May 16, 2012
Last verified: May 2012
History of Changes
  Purpose

Our study will enroll 644 randomly-selected Canadians who have been diagnosed with asthma by a physician within the previous five years. It will be determined what diagnostic tests were initially performed to make this diagnosis. Participants will undergo lung function testing over 6-8 weeks to determine their respiratory status and to confirm they have asthma. Participants may be followed up to one year depending on their test results.


Condition
Asthma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Strategies to Improve Diagnosis and Treatment of Asthma in Canadians

Resource links provided by NLM:

MedlinePlus related topics: Asthma
U.S. FDA Resources

Further study details as provided by Ottawa Hospital Research Institute:

Estimated Enrollment: 644
Study Start Date: November 2011
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Canadians diagnosed with Asthma and 18 years of age and older.

Criteria

Inclusion Criteria:

  1. Patient must have a recent diagnosis of asthma by a physician. Diagnosis of asthma must have occurred within 5 years prior to entry into the study.
  2. Patient must be at least 18 years old.

Exclusion Criteria:

  1. Patients in whom methacholine challenge is contraindicated

    • Patients using chronic oral prednisone.
    • Patients with heart attack or stroke within three previous months, and those with known aortic or cerebral aneurysms.
    • Pregnant patients (unknown effect of methacholine on the fetus) and breastfeeding patients (unknown whether methacholine is excreted in breast milk).
  2. Patients unable to provide informed consent.
  3. Patients not able to perform spirometry and/or methacholine challenge testing.
  4. Patients who have a greater than 10 pack-year smoking history (this will exclude patients with possible COPD).
  5. Patients who currently have active pulmonary Tuberculosis
  6. Patients who have had eye surgery in the past 3 months or who have a detached retina
  7. Patients involved in another interventional asthma study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01525381

Contacts
Contact: Shawn Aaron, MD 613-737-8899 ext 74729
Contact: Megan Beninger, RN 613-737-8899 ext 75130

Locations
Canada, Ontario
Ottawa Hospital Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Principal Investigator: Shawn Aaron, MD            
Sponsors and Collaborators
Ottawa Hospital Research Institute
  More Information

No publications provided

Responsible Party: Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier: NCT01525381     History of Changes
Other Study ID Numbers: 2011-221
Study First Received: January 31, 2012
Last Updated: May 16, 2012
Health Authority: Canada: Ethics Review Committee

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
 Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on May 19, 2013